(Alliance News) - IMD International Medical Devices Spa on Monday evening announced that, taking into account the information available to date, the group's growth trends remain unchanged for the time being. Turnover and Ebitda targets of around EUR50 million and EUR8 million respectively are planned for 2024.

In addition, the CEO disclosed the unaudited management figure of net financial debt, which as of September 30, 2023 shows a net cash position of about EUR5.1 million.

Aniello Aliberti - chairman and CEO - commented, "We want to reassure the market about the soundness of our development project. The year 2023 saw the manifestation of the aforementioned unfavorable dynamics that will lead us to close FY2023 in contraction compared to FY2022. We are confident that in FY 2024 we will recover the gap of approximately EUR4 million recorded in the current fiscal year but to generate further growth in line with current market conditions."

IMD International Medical Devices trades in the green by 4.7 percent at EUR1.34 per share

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Copyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.